VIRX – viracta therapeutics, inc. (US:NASDAQ)

News

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher [Yahoo! Finance]
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $13.00 to $11.00. They now have an "outperform" rating on the stock.
Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Viracta Therapeutics Announces New Employment Inducement Grants
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com